The p53 protein plays a critical role in the regulation of the cell cycle and apoptosis. This protein is often inactivated in various types of human cancer by abnormally high levels of its negative regulator, the Minute Double Mourine 2 (MDM2). As a result, the reactivation of p53 function by inhibiting the protein-protein p53-MDM2 interaction has been pointed as a promising strategy for cancer therapy. In 2004, 1,2,4,5-tetrasubstituted-4,5-cis-imidazolines, also known as Nutlins, were discovered through high throughput screening at Hoffman-La Roche as potent MDM2 inhibitors. However, the stereogenic centers present in the structure of the Nutlins prevents the use of simple synthetic routes towards them, which promotes the search for new small molecule inhibitors of MDM2. In this context, the 1,2,3-triazole system has been extensively studied and used in medicinal chemistry. Considering the vast experience of our group in this field, the objective of this work was to synthesize 1,2,3-triazole compounds as new molecular analogues to the Nutlins family.